X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DISHMAN PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DISHMAN PHARMA IPCA LABS/
DISHMAN PHARMA
 
P/E (TTM) x 39.5 25.1 157.2% View Chart
P/BV x 3.0 3.3 90.4% View Chart
Dividend Yield % 0.2 0.7 25.6%  

Financials

 IPCA LABS   DISHMAN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DISHMAN PHARMA
Mar-16
IPCA LABS/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs643374 171.7%   
Low Rs503129 390.1%   
Sales per share (Unadj.) Rs254.4197.8 128.6%  
Earnings per share (Unadj.) Rs16.121.2 75.8%  
Cash flow per share (Unadj.) Rs29.834.7 85.8%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.8 22.0%  
Book value per share (Unadj.) Rs194.6179.9 108.1%  
Shares outstanding (eoy) m126.2080.69 156.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.3 177.0%   
Avg P/E ratio x35.711.9 300.4%  
P/CF ratio (eoy) x19.27.2 265.5%  
Price / Book Value ratio x2.91.4 210.5%  
Dividend payout %6.29.4 66.0%   
Avg Mkt Cap Rs m72,30020,306 356.1%   
No. of employees `00013.30.8 1,604.7%   
Total wages/salary Rs m6,9605,355 130.0%   
Avg. sales/employee Rs Th2,413.519,252.7 12.5%   
Avg. wages/employee Rs Th523.26,459.5 8.1%   
Avg. net profit/employee Rs Th152.42,064.1 7.4%   
INCOME DATA
Net Sales Rs m32,10615,961 201.2%  
Other income Rs m226265 85.0%   
Total revenues Rs m32,33216,226 199.3%   
Gross profit Rs m4,4484,103 108.4%  
Depreciation Rs m1,7301,091 158.6%   
Interest Rs m241944 25.5%   
Profit before tax Rs m2,7032,334 115.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m675624 108.3%   
Profit after tax Rs m2,0281,711 118.5%  
Gross profit margin %13.925.7 53.9%  
Effective tax rate %25.026.7 93.5%   
Net profit margin %6.310.7 58.9%  
BALANCE SHEET DATA
Current assets Rs m17,34011,018 157.4%   
Current liabilities Rs m9,5599,517 100.4%   
Net working cap to sales %24.29.4 257.7%  
Current ratio x1.81.2 156.7%  
Inventory Days Days100110 90.8%  
Debtors Days Days5735 163.2%  
Net fixed assets Rs m20,77916,304 127.4%   
Share capital Rs m252161 156.4%   
"Free" reserves Rs m24,49912,907 189.8%   
Net worth Rs m24,55314,516 169.1%   
Long term debt Rs m3,5174,189 84.0%   
Total assets Rs m39,59529,805 132.8%  
Interest coverage x12.23.5 352.2%   
Debt to equity ratio x0.10.3 49.6%  
Sales to assets ratio x0.80.5 151.4%   
Return on assets %5.78.9 64.3%  
Return on equity %8.311.8 70.1%  
Return on capital %10.517.5 59.8%  
Exports to sales %48.624.8 196.2%   
Imports to sales %14.23.7 381.1%   
Exports (fob) Rs m15,6173,956 394.8%   
Imports (cif) Rs m4,571596 766.6%   
Fx inflow Rs m15,6174,952 315.4%   
Fx outflow Rs m5,828697 836.4%   
Net fx Rs m9,7904,255 230.1%   
CASH FLOW
From Operations Rs m2,7642,786 99.2%  
From Investments Rs m-1,432-1,529 93.6%  
From Financial Activity Rs m-1,591-941 169.1%  
Net Cashflow Rs m-259316 -81.8%  

Share Holding

Indian Promoters % 45.9 61.4 74.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 3.7 308.1%  
FIIs % 25.3 12.7 199.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 22.1 78.7%  
Shareholders   36,892 46,261 79.7%  
Pledged promoter(s) holding % 2.1 35.8 6.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   STERLING BIOTECH  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 22, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - PLETHICO PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS